Intelligence · Clinical Pipeline
Oncology · Phase I
Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.
- Programs
- 1,344
Quick answer
Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- Chinese Academy of 70 programs
- First People's Hospital 62 programs
- Takeda 49 programs
- United Therapeutics Europe 41 programs
- BEONE MEDICINES AUS 40 programs
- Anaxis Pharma 35 programs
- Regeneron UK 34 programs
- Janssen-Cilag International N.V 30 programs
- Novartis India 29 programs
- Chongqing Precision Biotech 27 programs
- Boehringer Ingelheim 26 programs
- BRIGHT MINDS BIOSCIENCES 23 programs
-
CB-012
Caribou Biosciences
Acute Myeloid Leukemia, in Relapse
1 trial -
CBG131 CAR-T Cell Infusion
The First People's Hospital of Lianyungang
Advanced Gastric and Pancreatic Cancer
1 trial -
CC-122
Bristol-Myers Squibb
Non-Hodgkin Lymphoma
1 trial -
CC-486
Celgene Europe Limited
Leukemia, Myeloid, Acute
1 trial -
CCT3833
United Therapeutics Europe Ltd
Melanoma
1 trial -
CD-001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Malignant Neoplasm
1 trial -
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
United Therapeutics Europe Ltd
HER2 Negative Breast Carcinoma
1 trial -
CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic
Xiyuan Hospital of China Academy of Chinese Medical Sciences
AML - Acute Myeloid Leukemia
1 trial -
CD19-CD22 CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
1 trial -
CD19-TriCAR-T/SILK
Biotech Pharmaceutical Co.,
Non-Hodgkin Lymphoma
1 trial -
CD19/CD20 Dual-CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Non-Hodgkin's Lymphoma
1 trial -
CD19/CD20 Dual-CAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
B-cell Leukemia
1 trial -
CD7 UCAR-T cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T-cell Leukemia
1 trial -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Metastatic Tumor
4 trials -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma
1 trial -
CD70 CAR-T cells
Chongqing Precision Biotech Co., Ltd
Ovarian Cancer
1 trial -
CD70-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Renal Cell Carcinoma (RCC)
1 trial -
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer
1 trial -
CEA CAR-T cells
Chongqing Precision Biotech Co., Ltd
Gastric Cancer
1 trial -
CEA protein antigen plus BCG Vaccine Mix for percutaneous use
Lxo Ireland Designated Activity Company
Rectal Cancer
1 trial -
CEA-targeted CAR-T (Intravenous)
Chongqing Precision Biotech Co., Ltd
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Lung Cancer
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Peritoneal Metastases From Colorectal Cancer
1 trial -
CEA-targeted CAR-T cells
Chongqing Precision Biotech Co., Ltd
Colorectal Cancer
1 trial -
CEND-1
LISATA THERAPEUTICS, INC.
Pancreatic Cancer
1 trial -
CEP-11981 (kinase inhibitor)
Teva Pharma GmbH
Cancer
1 trial -
CEP-37440
Teva Pharma GmbH
Solid Tumors
1 trial -
CEP-9722
Teva Pharma GmbH
Solid Tumor
1 trial -
CEP-9722
Teva Pharma GmbH
Solid Tumors or Mantle Cell Lymphoma
1 trial -
CFT1946
C4 Therapeutics
Solid Tumors
1 trial -
CFT8634
C4 Therapeutics
Synovial Sarcoma
1 trial -
CG-806
Aptose Biosciences
Acute Myeloid Leukemia
1 trial -
CG-806
Aptose Biosciences
Chronic Lymphocytic Leukemia
1 trial -
CG0070
CG Oncology
Muscle-Invasive Bladder Carcinoma
1 trial -
CGT4255
Cogent Biosciences
Advanced Solid Tumor, Adult
1 trial -
CHR-2797 (tosedostat)
United Therapeutics Europe Ltd
Advanced Solid Tumors
1 trial -
CHS-006 (anti-TIGIT)
Coherus Oncology
Advanced Solid Tumor
1 trial -
CHS-1000
Coherus Oncology
Advanced or Metastatic Solid Tumors
1 trial -
CHS-114
Coherus Oncology
Advanced Solid Tumor
1 trial -
CHS-114
Coherus Oncology
Metastatic Solid Tumor
1 trial -
CHS-388
Coherus Oncology
Advanced Solid Tumor
1 trial -
CITY
Pari Pharma GmbH
Cutaneous T-cell lymphomas (CTCL)
1 trial -
CLADRIBINE DOSE ESCALATION IN CONDITIONING REGIMEN PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (Allo-HSCT) FOR REFRACTORY ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
The George Institute
Acute leukemia and myelodysplastic syndromes
1 trial -
CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer
The George Institute
Patients with recurrent and/or metastatic solid cancer.
1 trial -
CLL1 and CD38 Dual-Target CAR-T Cell Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Myeloid Leukemia
1 trial -
CLN-049
Cullinan Therapeutics
Relapsed/Refractory Acute Myeloid Leukemia (AML)
1 trial -
CLN-617
Cullinan Therapeutics
Advanced Solid Tumor
1 trial -
CLN-619
Cullinan Therapeutics
Advanced Solid Tumor
1 trial
Frequently asked questions
How many oncology Phase I programs exist?
1,344 programs match both the therapeutic area and stage filters in our published index.
Data attribution: Data sources · All pipeline programs